Page 36 - 2019_03-Haematologica-web

B. Wang et al.
27. Lam KC, Lai CL, Trepo C, et al. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med. 1981;304(7):380-386.
28. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988;167(2):630-633.
29. Cheng AL, Hsiung CA, Su IJ, et al. Steroid- free chemotherapy decreases risk of hepati- tis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6): 1320-1328.
30. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102(5):1930.
31. Sarrecchia C, Cappelli A, Aiello P. HBV reac- tivation with fatal fulminating hepatitis dur- ing rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11(4):189- 191.
32. Law JK, Ho JK, Hoskins PJ, et al. Fatal reacti- vation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen- negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005;46(7):1085-1089.
33. Yamagata M, Murohisa T, Tsuchida K, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma. 2007;48(2):431-433.
34. Dillon R, Hirschfield GM, Allison ME, et al. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ. 2008;337:a423.
35. Kusumoto S, Arcaini L, Hong X, et al. Risk fo HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rit- uximab immunochemotherapy. Blood. 2019;133(2):137-146.
36. Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91(7):1007-1012.
37. Visco C, Finotto S. Hepatitis C virus and dif- fuse large B-cell lymphoma: Pathogenesis behavior and treatment. World J Gastroenterol. 2014;20(32):11054-11061.
38. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alem- tuzumab therapy. Eur J Haematol. 2005;74(3):254-258.
39. Moses SE, Lim ZY, Sudhanva M, et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiv- ing reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol. 2006;78(12):1560-1563.
40. Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis B virus infection a patient with adult T-cell leukemia-lym- phoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45(13):1363-1367.
41. Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infec- tion in adult T-cell leukemia-lymphoma patients with resolved HBV infection fol- lowing systemic chemotherapy. Int J Hematol. 2015;101(4):398-404.
42. Yang H, Cao Z, Wang Z, et al. Hepatitis B virus reactivation induced by brentuximab vedotin in the treatment of Hodgkin lym- phoma: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi.
2014;35(10):949-950.
43. Seto WK, Chan TS, Hwang YY, et al.
Hepatitis B reactivation in occult viral carri- ers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology. 2017;65(5):1451-1461.
with ruxolitinib. Ann Haematol. 2014;93
(6):1075-1076.
59. Caocci G, Murgia F, Podda L, et al.
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1): 225-227.
60. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a compre- hensive review. Eur J Cancer. 2016;54:139-
44. Lindemann M, Koldehoff M, Fiedler M, et
al. Control of hepatitis B virus infection in hematopoietic stem cell recipients after
receiving grafts from vaccinated donors.
Bone Marrow Transplant. 2016;51(3):428-
431. 148.
45. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosup- pressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209-219.
46. Jun CH, Kim BS, Oak CY, et al. HBV reacti- vation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int. 2017;11(1):87-95.
47. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124 (3):374-384.
48. Huang H, Cai Q, Lin T, et al. Lamivudine for the prevention of hepatitis B virus reactiva- tion after high-dose chemotherapy and autologous hematopoietic stem cell trans- plantation for patients with advanced or relapsed non-Hodgkin’s lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-2406.
49. Varma A, Biritxinaga L, Saliba RM, et al. Impact of hepatitis B core antibody seropos- itivity on the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2017;23(4):581-587.
50. Harris AE, Styczynski J, Bodge M, et al. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunopro- tection? Bone Marrow Transplant. 2015;50 (7):899-903.
51. Lindemann M, Barsegian V, Runde V, et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation. 2003;75(6): 833-838.
52. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47(1): 155-157.
53. Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19(8):1318- 1321.
54. Lakhani S, Davidson L, Priebat DA, et al. Reactivation of chronic hepatitis B infection related to imtinib mesylate therapy. Hepatol Int. 2008;2(4):498-499.
55. Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treat- ment with imatinib rescued by liver trans- plantation: case report and literature review. Int J Haematol. 2009;90(3):383-387.
56. De Jesus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belgica. 2015;78(4):424-426.
57. Li J, Huang B, Li Y, et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regiments followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56(6): 1710-1717.
58. Shen CH, Hwang CE, Chen YY, et al. Hepatitis B virus reactivation associated
61. Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor- related immune hepatitis. J Gastrointest Oncol. 2018;9(1):220-224.
62. Koksal AS, Toka B, Eminler AT, et al. HBV- related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann Oncol. 2017;28 (12):3103-3104.
63. Pandey A, Ezemenari S, Liaukovich M, et al. A rare case of Pembrolizumab-induced reac- tivation of hepatitis B. Case Rep Oncol Med. 2018;2018:5985131.
64. Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver. 2018;12(5):497-507.
65. Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43-56.
66. Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27(1):15-19.
67. Huang YH, Hsiao LT, Hong YC, et al. Randomised controlled trial of entecavir prophylaxis for rituximab-associated hepati- tis B virus reactivation in patients with lym- phoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772.
68. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125 (6):1742-1749.
69. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in non- Hodgkin’s lymphoma: a randomised trial. Hepatology. 2008;47(3):844-853.
70. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation dur- ing chemotherapy. Ann Intern Med. 2008;148(7):519-528.
71. Kohrt HE, Ouyang DL, Keefe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24(7):1003-1016.
72. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-neg- ative patients receiving lamivudine therapy. Hepatology. 2000;32(5):1145-1153.
73. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a ran- domized control trial. JAMA. 2014;312(23): 2521-2530.
74. Hilgendorf I, Loebermann M, Borchert K, et al. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. Bone Marrow Transplant. 2011;46 (9):1274-1275.
75. Woodward CLN, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone tox- icity. HIV Med. 2009;10(8):482-487.
76. Agarwal K, Brunetto M, Seto WK, et al. 96
442
haematologica | 2019; 104(3)